SNCA and Parkinson disease: Dapagliflozin (1 mg/kg/day, for 3 weeks) improved motor coordination, diminished the expression of α-synuclein and related pathological alterations, augmented the level of expression of tyrosine hydroxylase and, consequently, dopamine in the basal ganglia, and reduced oxidative stress and neuroinflammation (by decreasing the activity of the NF-κB pathway and TNF-α levels) of a PD rodent model [311].